No bulky books, just short cut Questions of 1D0-525 exam

killexams.com 1D0-525 practice test involves a Comprehensive Pool of 1D0-525 Issues and Answers having mock exam validated and approved along with personal references and explanations. Each of our objectives to train the 1D0-525 Questions and even Answers is not merely to pass typically the 1D0-525 test at typically the first attempt although Really Improve Your current Knowledge about typically the 1D0-525 test subjects.

Exam Code: 1D0-525 Practice test 2022 by Killexams.com team
1D0-525 CIW E-Commerce Designer

Exam Title : CIW E-Commerce Specialist
Exam ID : 1D0-525
Exam Center Fee : $150 (USD)
Exam Duration : 75 mins
Questions in test : 72
Passing Score : 68%
Exam Center : Pearson VUE
Real Questions : CIW E-Commerce Specialist Real Questions
VCE practice test : CIW 1D0-525 Certification VCE Practice Test


Details

E-Commerce Site Development
- Evaluate an e-commerce site to maximize audience usability.
- Develop and host an e-commerce site using instant storefront services and stand-alone e-commerce software.
- Implement e-commerce-based learning solutions.
- Implement inventory and fulfillment strategies for an e-commerce site.
- Implement payment-processing services for an e-commerce site.
- Develop a knowledge base.

E-Commerce Technology and Security
- Define and use standards, initiatives and e-commerce frameworks that support supplier transactions.
- Configure Web server software for an e-commerce site.
- Analyze and Improve e-commerce site performance.
- Secure e-commerce transactions.
- Secure an e-commerce site.

E-Commerce Business, Marketing and Legal Issues
- Identify the effects of e-commerce on business operations and revenue generation.
- Identify legal and governmental issues in e-commerce.
- Implement effective marketing for an e-commerce site.
- Implement strategies for effective customer service and manage customer relationships in e-commerce operations.

CIW E-Commerce Designer
CIW test format
Killexams : CIW test format - BingNews http://www.bing.com:80/news/search?q=CIW+exam+format&cc=us&format=RSS Search results Killexams : CIW test format - BingNews http://www.bing.com:80/news/search?q=CIW+exam+format&cc=us&format=RSS https://killexams.com/exam_list/CIW Killexams : Frequency Format Diagram and Probability Chart for Breast Cancer Risk Communication: A Prospective, Randomized Trial

Results

Of the 154 subjects who expressed an interest in the study, 150 provided informed consent and completed the previsit questionnaire; 74 patients (34 younger, 40 older) were randomly assigned to the BG group and 76 to the BG+FF group (36 younger, 40 older) (Figure 1). Four participants did not complete the postvisit questionnaire; all of them were in the BG group and were included in the study analyses (as detailed in the Methods).

Participants' demographic characteristics are shown in Table 1 . Mean ± SD age of the study participants was 60.2 ± 10 years (range, 41–83 years). Most subjects were white (88%), had at least a high school education (97%), and had at least some college education (70%). No significant differences were observed between the 2 groups with regard to education, Gail model 5-year risk of invasive breast cancer, family history of breast cancer, number of prior breast biopsies, use of hormone replacement therapy, menopausal status, or previsit risk perception ( Table 1 ).

The Gail model 5-year risk of invasive breast cancer was between 2% and 9% for 81% of the overall cohort; 17% had a risk score of < 2%, and 2% of the trial had a score of 10% to 49% ( Table 1 ). On the previsit questionnaire, 72% of the overall cohort overestimated their risk of breast cancer.

In the overall assessment of risk perception, accurate risk perception was noted for 14 women (4 younger, 10 older; 19%) in the BG group before the visit and improved to 45 women (21 younger, 24 older; 61%) after the visit, whereas in the BG+FF group, the accuracy of risk perception improved from 10 women (6 younger, 4 older; 13%) before the visit to 51 women (26 younger, 25 older; 67%) after the visit. The previsit to postvisit changes in accurate risk perception are detailed in Figure 3. Of the 15 women in the BG group with risk score < 2%, 3 (20%) had accurate risk perception before the visit; this increased to 8 patients (53%) after the visit. For the 11 women in the BG+FF group with risk score < 2%, accurate risk perception increased from 1 patient (9%) previsit to 6 patients (55%) postvisit. The overall difference in level of improvement between the BG and BG+FF groups was not significant (P = .10 by the Pearson χ2 test and P = .29 by logistic regression when previsit score and age were in the model); age also did not affect the scores (P = .57).

Figure 3.

Proportion of subjects providing accurate previsit and postvisit estimates of breast cancer risk. Subjects are stratified by group (BG or BG+FF) and their real Gail model level of risk. Bars reflect the percentage of accurate previsit and postvisit estimates of risk based on the number of women accurately estimating that level of risk (numbers above bars) and the number of women in each risk category (numbers below bars).

The results of the previsit and postvisit questionnaires, depicting patients' self-reported estimates of their risk compared with the real Gail risk model results, are shown in Table 2 . Although 121 (81%) of the overall group had a Gail risk score of 2% to 9%, only 15 women (20%) in the BG group and 13 women (17%) in the BG+FF group estimated this risk on the previsit questionnaire, with 11 and 9 women, respectively, giving accurate responses (Figure 3). However, on the postvisit questionnaire, 40 women (54%) in the BG group and 47 (62%) in the BG+FF group estimated this level of risk, which was an accurate risk estimation for 36 and 44 women, respectively. This increase constituted an improvement in risk estimation for both groups, but the difference between groups was not significant (P = .17).

Although none of the women in the study had Gail model risk estimates of 50% or greater, 21 women (28%) in the BG group and 17 (22%) in the BG+FF group reported such high risk on the previsit questionnaire ( Table 2 ). Of interest, after risk education, 14 women (19%) in the BG group still reported risk of 50% or higher, whereas only 2 women (3%) in the BG+FF group reported this high level of risk (P = .004). The difference between previsit and postvisit perception of high risk was greater in the BG+FF group (88% decrease) than in the BG group (33% decrease) (P < .001).

In response to the question assessing preference for presentation of risk information, asked only of women who saw both formats (BG+FF group), 34% (n = 26) "preferred frequency format," 15% (n = 11) "preferred bar graph," 43% (n = 33) felt that "both were just as good," and 8% (n = 6) had "no preference/don't know."

Wed, 03 Aug 2022 11:59:00 -0500 en text/html https://www.medscape.com/viewarticle/585056_3
Killexams : Steve Bannon Agrees to Cooperate with January 6 Committee after Trump Waives Executive-Privilege Claim

Steve Bannon, the former chief strategist for President Trump who is awaiting trial on charges of contempt of Congress, has agreed to cooperate with the January 6 committee.

Bannon wrote in an email to the panel, first obtained by the Guardian, that he was open to appearing for a public hearing after receiving a letter from Trump waiving his executive privilege. The email restated that Bannon had felt obligated to refuse the original congressional subpoena from the committee because Trump had claimed executive privilege over his testimony.

“When you first received the Subpoena to testify and provide documents, I invoked Executive Privilege. However, I watched how unfairly you and others have been treated, having to spend vast amounts of money on legal fees, and all of the trauma you must be going through for the love of your Country, and out of respect for the Office of the President,” Trump said in the letter to Bannon.

Some argued that Trump’s executive privilege declaration didn’t apply to Bannon, who was not a White House employee, and contradicted a Supreme Court ruling that a current president’s waiver for executive privilege overrides a former president’s claim of it.

“If you reach an agreement on a time and place for your testimony, I will waive Executive Privilege for you, which allows you to go in and testify truthfully and fairly,” Trump said in giving his blessing to Bannon.

Democratic committee member and congresswoman Zoe Lofgren (Calif.) remarked on CNN’s State of the Union on Sunday that she believes the panel will arrange a meeting with Bannon.

“I expect that we will be hearing from him,” Lofgren said. “And there are many questions that we have for him.”

However, she expressed doubt that the testimony would delivered via a public hearing, which can be very extensive, per Bannon’s wishes since the committee usually does depositions.

“This goes on for hour after hour after hour. We want to get all our questions answered, and you can’t do that in a live format,” she said.

“While Mr. Bannon has been steadfast in his convictions, circumstances have now changed,” Bannon attorney Bob Costello confirmed in a letter to the committee. “Mr. Bannon is willing to, and indeed prefers, to testify at your public hearing.”

The panel is likely to probe Bannon about his December 2020 conversations with Trump in the lead-up to the certification of the presidential election results. Bannon will also likely be scrutinized for any potential involvement in the January 6 riot, specifically the comments he made on a podcast the day before on January 5 that “All hell is going to break loose tomorrow.”

More from National Review

Sun, 10 Jul 2022 06:38:00 -0500 en-GB text/html https://uk.news.yahoo.com/steve-bannon-agrees-cooperate-january-164913937.html Killexams : New Cryo-Plasma Focused Ion Beam to Streamline Cellular Cryo-Electron Tomography Research

Thermo Scientific Arctis Cryo-Plasma FIB enables speed and consistency of cellular cryo-electron tomography

HILLSBORO, Ore., August 01, 2022--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Thermo Scientific Arctis Cryo-Plasma Focused Ion Beam (Cryo-PFIB), a new connected and automated microscope designed to advance the pace of cryo-electron tomography (cryo-ET) research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005011/en/

Thermo Scientific Arctis Cryo-Plasma Focused Ion Beam (Cryo-PFIB) (Graphic: Business Wire)

Cryo-ET makes it possible to study how proteins and other molecules operate together in a cellular context, at resolutions unsurpassed by other microscopy techniques, and has enormous potential for cell biology research, including the study of infectious disease, neurodegenerative disease, and other globally impactful structural biology applications. However, the process of preparing optimal samples for cryo-ET is still time-consuming and complex.

The Arctis Cryo-PFIB helps users address these challenges with advanced automation and new connectivity capabilities within the workflow, significantly increasing throughput compared to other commercially available solutions for fast, reproducible production of samples for cryo-ET.

"Our goal is to provide an end-to-end cryo-ET workflow for new and experienced users," said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher. "By expanding our automation capabilities to our cryo-PFIB portfolio, we can pave the way for cryo-ET to become a frontier technique for cell biology."

The system is designed to provide high-quality samples with consistent thickness while minimizing trial contamination risks. Users will benefit from integrated correlative microscopy, dedicated Plasma FIB technology, advanced automation and new connectivity capabilities, including simplified trial loading and transfer. Highlights include:

  • Integrated correlative light and electron microscopy (CLEM) for quick targeting of the area of biological interest.

  • Plasma FIB technology for rapid removal of large trial volumes and quick access to areas of biological interest.

  • Automation capabilities to simplify trial preparation and enable remote operation, allowing for long automated runs, reproducible results and higher throughput compared to current gallium-based cryo-FIB solutions.

  • Connectivity in the workflow for simplifying the transfer of samples to the Thermo Scientific Krios or Glacios Cryo-TEMs. The Arctis Cryo-PFIB comes with Thermo Fisher’s industry-leading Autoloader which robotically loads cassettes with up to 12 grids. New dedicated TomoGrids are designed to achieve optimal alignment of the lamella to the TEM tilt axis.

"Through a strategic effort with Thermo Fisher Scientific on the build of this innovative cryo-PFIB, we hope to increase—by a factor of ten—the number of biological specimens that can be prepared for analysis by structural biology, and pioneer large volume cryo-ET," said Jim Naismith, director of The Rosalind Franklin Institute and collaborator in the development of the Thermo Scientific Arctis Cryo-PFIB.

Thermo Fisher Scientific and The Rosalind Franklin Institute began working together in 2019, using existing technology to understand and determine what’s next for cryo-EM, and where innovation would be needed to create the next generation of instrumentation.

"Our joint ambition to drive scientific and technological breakthroughs, and our goal of increasing access to cryo-EM to as many scientists as possible, make The Rosalind Franklin Institute and Thermo Fisher Scientific ideal collaborators," added Naismith. "We will continue to work together to democratize the technique and create incremental yet impactful improvements to the workflow."

Learn more about the Thermo Scientific Arctis Cryo-PFIB: https://ter.li/d2gsjm

Register for the product launch webinar on September 21: https://ter.li/ydkoho

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005011/en/

Contacts

Media Contact Information:
Brianna Radicioni
Thermo Fisher Scientific
+1 617-390-3924
brianna.radicioni@thermofisher.com

Mon, 01 Aug 2022 00:00:00 -0500 en-GB text/html https://uk.news.yahoo.com/cryo-plasma-focused-ion-beam-120000384.html Killexams : Frequency Format Diagram and Probability Chart for Breast Cancer Risk Communication: A Prospective, Randomized Trial

Abstract and Background

Abstract

Background: Breast cancer risk education enables women make informed decisions regarding their options for screening and risk reduction. We aimed to determine whether patient education regarding breast cancer risk using a bar graph, with or without a frequency format diagram, improved the accuracy of risk perception.
Methods: We conducted a prospective, randomized trial among women at increased risk for breast cancer. The main outcome measurement was patients' estimation of their breast cancer risk before and after education with a bar graph (BG group) or bar graph plus a frequency format diagram (BG+FF group), which was assessed by previsit and postvisit questionnaires.
Results: Of 150 women in the study, 74 were assigned to the BG group and 76 to the BG+FF group. Overall, 72% of women overestimated their risk of breast cancer. The improvement in accuracy of risk perception from the previsit to the postvisit questionnaire (BG group, 19% to 61%; BG+FF group, 13% to 67%) was not significantly different between the 2 groups (P = .10). Among women who inaccurately perceived very high risk (≥ 50% risk), inaccurate risk perception decreased significantly in the BG+FF group (22% to 3%) compared with the BG group (28% to 19%) (P = .004).
Conclusion: Breast cancer risk communication using a bar graph plus a frequency format diagram can Improve the short-term accuracy of risk perception among women perceiving inaccurately high risk.

Background

A patient's knowledge of risks and benefits is crucial to informed decision making.[1] A woman's understanding of her breast cancer risk is, therefore, potentially important in her choice of breast cancer screening options or risk-reduction strategies. The ability to clearly and accurately convey the estimate of breast cancer risk is a vital component of patient education that can enable a woman to make an informed decision. Previous studies have shown that women tend to overestimate their risk of breast cancer.[2,3] To decrease such misinterpretations of risk, it is imperative that women be presented information regarding their estimated risk of breast cancer in an understandable format tailored to their level of understanding.

In a report on risk communication, Lipkus and Hollands[4] showed that visual displays enhance the understanding of numerical risk. Furthermore, in a qualitative study using focus groups, women preferred a frequency format diagram to probability estimates for communicating risk estimates.[5] A review of the literature addressing the efficacy of breast cancer risk communication showed that, of several modalities used to communicate risk, no single modality was the most efficacious.[6] In a study assessing which formats are most accurately perceived by patients, Feldman-Stewart et al[7] reported that, for making a choice, systematic ovals, bars (horizontal or vertical), and numbers were equally well perceived, whereas for estimating magnitude of risk, numbers led to the most accurate estimates. Bogardus and colleagues[1] emphasized the importance of research for ascertaining the best techniques to communicate risks in the clinical setting. Although several studies have analyzed risk communication, few have been randomized trials,[2] and none, to our knowledge, have been randomized trials comparing the efficacy of specific formats of communicating risk among women at high risk for breast cancer.

We conducted a prospective, randomized trial to compare communication of breast cancer risk using a bar graph (standard of care) versus the bar graph in addition to a frequency format diagram (using highlighted human figures) among women at increased risk of breast cancer. The aim of this study was to determine whether patient education regarding breast cancer risk using a bar graph alone or with the addition of a frequency format diagram improved the accuracy of risk perception and to assess women's preference for risk information provided as a bar graph versus in a frequency format.

Thu, 04 Aug 2022 12:00:00 -0500 en text/html https://www.medscape.com/viewarticle/585056_1
1D0-525 exam dump and training guide direct download
Training Exams List